Skip to main content
SpringerLink
Log in

Task Force Report on “Non-criteria” Antiphospholipid Antibody Tests

  • Chapter
  • First Online:
Antiphospholipid Syndrome

  • 638 Accesses

Abstract

Current classification criteria for antiphospholipid syndrome (APS) recommend the use of one or more of three positive standardized laboratory assays to detect antiphospholipid antibodies (aPL) in the presence of at least one of the two major clinical manifestations (i.e., thrombosis or pregnancy morbidity). However, several other autoantibodies shown to be directed against phospholipids other than cardiolipin and/or their complexes with proteins of the coagulation cascade have also been proposed to be important in APS. This chapter summarizes the recommendations of a Task Force of worldwide scientists who discussed and analyzed critical questions related to “noncriteria” aPL tests in an evidence-based manner, during the 13th International Congress on Antiphospholipid Antibodies (APLA 2010, April 13–16, 2010, Galveston, TX).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  PubMed  CAS  Google Scholar 

  2. Bertolaccini ML, Hughes GR, Khamashta MA. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab. 2004;50:653–65.

    PubMed  CAS  Google Scholar 

  3. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study–NOHA. Thromb Haemost. 2000;84:228–36.

    PubMed  CAS  Google Scholar 

  4. Sugi T, Matsubayashi H, Inomo A, Dan L, Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res. 2004;30:326–32.

    Article  PubMed  Google Scholar 

  5. Sanmarco M, Bardin N, Camoin L, et al. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization. Ann N Y Acad Sci. 2007;1108:457–65.

    Article  PubMed  CAS  Google Scholar 

  6. Bertolaccini ML, Roch B, Amengual O, Atsumi T, Khamashta MA, Hughes GRV. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol. 1998;37:1229–32.

    Article  PubMed  CAS  Google Scholar 

  7. Sanmarco M, Gayet S, Alessi MC, et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost. 2007;97:949–54.

    PubMed  CAS  Google Scholar 

  8. Bertolaccini ML, Amengual O, Atsumi T, et al. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20:191–205.

    Article  PubMed  CAS  Google Scholar 

  9. Velayuthaprabhu S, Matsubayashi H, Sugi T, et al. A unique preliminary study on placental apoptosis in mice with passive immunization of anti-phosphatidylethanolamine antibodies and anti-factor XII antibodies. Am J Reprod Immunol. 2011;66:373–84 [Epub ahead of print].

    Article  PubMed  CAS  Google Scholar 

  10. de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 2006;107:1916–24.

    Article  PubMed  CAS  Google Scholar 

  11. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95:15542–6.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Iverson GM, Reddel S, Victoria EJ, et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol. 2002;169:7097–103.

    Article  PubMed  CAS  Google Scholar 

  13. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007;56:280–90.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540–5.

    Article  PubMed  CAS  Google Scholar 

  15. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–73.

    Article  PubMed  Google Scholar 

  16. Banzato A, Pozzi N, Frasson R, et al. Antibodies to domain I of beta(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res. 2011;128:583–6.

    Article  PubMed  CAS  Google Scholar 

  17. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7:833–42.

    Article  PubMed  CAS  Google Scholar 

  18. Laroche P, Berard M, Rouquette AM, Desgruelle C, Boffa MC. Advantage of using both anionic and zwitterionic phospholipid antigens for the detection of antiphospholipid antibodies. Am J Clin Pathol. 1996;106:549–54.

    PubMed  CAS  Google Scholar 

  19. Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol. 1997;89:549–55.

    Article  PubMed  CAS  Google Scholar 

  20. Fialova L, Mikulikova L, Matous-Malbohan I, Benesova O, Zwinger A. Prevalence of various antiphospholipid antibodies in pregnant women. Physiol Res. 2000;49:299–305.

    PubMed  CAS  Google Scholar 

  21. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Hum Reprod. 2002;17:2981–5.

    Article  PubMed  CAS  Google Scholar 

  22. Amoroso A, Mitterhofer AP, Del Porto F, et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol. 2003;64:265–73.

    Article  PubMed  CAS  Google Scholar 

  23. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod. 1997;56:50–8.

    Article  PubMed  CAS  Google Scholar 

  24. Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol. 2003;101:455–62.

    Article  PubMed  CAS  Google Scholar 

  25. Greco TP, Amos MD, Conti-Kelly AM, Naranjo JD, Ijdo JW. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus. 2000;9:33–41.

    Article  PubMed  CAS  Google Scholar 

  26. Wilson WA, Faghiri Z, Taheri F, Gharavi AE. Significance of IgA antiphospholipid antibodies. Lupus. 1998;7:S110–3.

    Article  PubMed  CAS  Google Scholar 

  27. Weidmann CE, Wallace DJ, Peter JB, Knight PJ, Bear MB, Klinenberg JR. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol. 1988;15:74–9.

    PubMed  CAS  Google Scholar 

  28. Tajima C, Suzuki Y, Mizushima Y, Ichikawa Y. Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. J Rheumatol. 1998;25:1730–6.

    PubMed  CAS  Google Scholar 

  29. Lopez LR, Santos ME, Espinoza LR, La Rosa FG. Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Clin Pathol. 1992;98:449–54.

    PubMed  CAS  Google Scholar 

  30. Molina JF, Gutierrez-Urena S, Molina J, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol. 1997;24:291–6.

    PubMed  CAS  Google Scholar 

  31. Wong KL, Liu HW, Ho K, Chan K, Wong R. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol. 1991;18:1187–92.

    PubMed  CAS  Google Scholar 

  32. Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci. 1999;318:55–60.

    Article  PubMed  CAS  Google Scholar 

  33. Kalunian KC, Peter JB, Middlekauff HR, et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med. 1988;85:602–8.

    Article  PubMed  CAS  Google Scholar 

  34. Pierangeli SS, Liu XW, Barker JH, Anderson G, Harris EN. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995;74:1361–7.

    PubMed  CAS  Google Scholar 

  35. Lakos G, Kiss E, Regeczy N, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999;117:574–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  36. Lee RM, Brown MA, Branch DW, Ward K, Silver RM. Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia. Obstet Gynecol. 2003;102:294–300.

    Article  PubMed  CAS  Google Scholar 

  37. Staub HL, Norman GL, Crowther T, et al. Antibodies to the atherosclerotic plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr. 2003;61:757–63.

    Article  PubMed  Google Scholar 

  38. Staub HL, Franck M, Ranzolin A, Norman GL, Iverson GM, von Muhlen CA. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev. 2006;6:104–6.

    Article  PubMed  CAS  Google Scholar 

  39. Ranzolin A, Bohn JM, Norman GL, et al. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol. 2004;83:37–40.

    Google Scholar 

  40. Staub HL, von Muhlen CA, Norman GL. Beta2-glycoprotein I IgA antibodies and ischaemic stroke. Rheumatology (Oxford). 2006;45:645–6.

    Article  CAS  Google Scholar 

  41. Franck M, Staub HL, Petracco JB, et al. Autoantibodies to the atheroma component beta2-glycoprotein I and risk of symptomatic peripheral artery disease. Angiology. 2007;58: 295–302.

    Article  PubMed  CAS  Google Scholar 

  42. Yamada H, Tsutsumi A, Ichikawa K, Kato EH, Koike T, Fujimoto S. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum. 1999;42:2727–8.

    Article  PubMed  CAS  Google Scholar 

  43. Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol. 2001;185:748–53.

    Article  PubMed  CAS  Google Scholar 

  44. Mehrani T, Petri M. Association of IgA anti-β2 glycoprotein i with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol. 2011;38:64–8.

    Article  PubMed  Google Scholar 

  45. Kumar S, Papalardo E, Sunkureddi P, Najam S, Gonzalez EB, Pierangeli SS. Isolated elevation of IgA anti-beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus. 2009;18:1011–4.

    Article  PubMed  CAS  Google Scholar 

  46. Martinez-Martinez LA, Aguilar-Valenzuela R, Seif A, Binder W, Alarcon GS, Pierangeli S. Do clinically relevant IgA anti-β2glycoprotein I (anti-β2GPI) antibodies bind to DIV/V of β2GPI? Lupus. 2010;19:C130 (abstract).

    Article  Google Scholar 

  47. Gabeta S, Norman GL, Gatselis N, et al. IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol. 2008;28:501–11.

    Article  PubMed  CAS  Google Scholar 

  48. Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Casciola-Rosen L. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum. 2009;60:2480–9.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Akhter E, Binder W, Shums Z, Magder L, Petri M. Novel antiphospholipid antibodies and stroke in SLE. Lupus. 2010;19:C124 (abstract).

    Google Scholar 

  50. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120–5.

    PubMed  CAS  Google Scholar 

  51. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997;77:486–91.

    PubMed  CAS  Google Scholar 

  52. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005;93:289–97.

    PubMed  CAS  Google Scholar 

  53. Pengo V, Biasolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid reactive antibodies. Thromb Haemost. 1996;75:721–4.

    PubMed  CAS  Google Scholar 

  54. Bertolaccini ML, Atsumi T, Khamashta MA, Amengual O, Hughes GR. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol. 1998;25:1104–8.

    PubMed  CAS  Google Scholar 

  55. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost. 1996;75: 456–9.

    PubMed  CAS  Google Scholar 

  56. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost. 1996;76:916–24.

    PubMed  CAS  Google Scholar 

  57. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3:1231–8.

    Article  PubMed  CAS  Google Scholar 

  58. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost. 2007;5:1158–64.

    Article  PubMed  CAS  Google Scholar 

  59. Forastiero R, Martinuzzo M, Iglesias Varela ML, Cerrato G. Multiple (triple or quadruple) aPL positivity is much more prevalent in patients with definite antiphospholipid syndrome. Lupus. 2010;19:C109 (abstract).

    Article  Google Scholar 

  60. Funke A, Bertolaccini ML, Atsumi T, Amengual O, Khamashta MA, Hughes GRV. Autoantibodies to prothrombin-phosphatidylserine complex: clinical significance in systemic lupus erythematosus. Arthritis Rheum. 1998;41:S240 (abstract).

    Google Scholar 

  61. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43:1982–93.

    Article  PubMed  CAS  Google Scholar 

  62. Atsumi T, Koike T. Antiprothrombin antibody: why do we need more assays? Lupus. 2010;19:436–9.

    Article  PubMed  CAS  Google Scholar 

  63. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon. Blood. 1998;92:1652–60.

    PubMed  CAS  Google Scholar 

  64. Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003;163:1193–200.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  65. Hanly JG, Smith SA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol. 2000;120:537–43.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  66. Gaspersic N, Ambrozic A, Bozic B, Majhenc J, Svetina S, Rozman B. Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-beta2-glycoprotein I and anti-annexin A5 antibodies. Rheumatology (Oxford). 2007;46:81–6.

    Article  CAS  Google Scholar 

  67. Tomer A, Bar-Lev S, Fleisher S, Shenkman B, Friger M, Abu-Shakra M. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol. 2007;139:113–20.

    Article  PubMed  CAS  Google Scholar 

  68. Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004;104:2783–90.

    Article  PubMed  CAS  Google Scholar 

  69. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007;109:1490–4.

    Article  PubMed  CAS  Google Scholar 

  70. Rand JH, Arslan AA, Wu XX, et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol. 2006;194:182–8.

    Article  PubMed  CAS  Google Scholar 

  71. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res. 2004;114:593–5.

    Article  PubMed  CAS  Google Scholar 

  72. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530–6.

    Article  PubMed  CAS  Google Scholar 

  73. Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med. 1995;99:624–8.

    Article  PubMed  CAS  Google Scholar 

  74. Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK. Anticardiolipin antibodies are not an independent risk factor for stroke: An incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke. 2000;31:1289–93.

    Article  PubMed  CAS  Google Scholar 

  75. Brey RL, Abbott RD, Curb JD, et al. Beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke. 2001;32:1701–6.

    Article  PubMed  CAS  Google Scholar 

  76. van Goor MP, Alblas CL, Leebeek FW, Koudstaal PJ, Dippel DW. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol Scand. 2004;109:410–5.

    Article  PubMed  Google Scholar 

  77. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997–1002.

    Article  PubMed  CAS  Google Scholar 

  78. Sanmarco M. ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results. J Immunol Methods. 2010;358:9–16.

    Article  PubMed  CAS  Google Scholar 

  79. Arad A, Proulle V, Furie RA, Furie BC, Furie B. beta-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 2011;117:3453–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  80. Tebo AE, Jaskowski TD, Phansalkar AR, Litwin CM, Branch DW, Hill HR. Diagnostic performance of phospholipid-specific assays for the evaluation of antiphospholipid syndrome. Am J Clin Pathol. 2008;129:870–5.

    Article  PubMed  Google Scholar 

  81. Tebo AE, Jaskowski TD, Hill HR, Branch DW. Clinical relevance of multiple antibody specificity testing in anti-phospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol. 2008;154:332–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  82. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 1995;73:529–34.

    PubMed  CAS  Google Scholar 

  83. Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: Induction of aPL by viral peptides. Lupus. 1998;7 suppl 2:S52–4.

    Article  PubMed  CAS  Google Scholar 

  84. Sweiss NJ, Bo R, Kapadia R, et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One. 2010;5:e12280.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  85. Bizzaro N, Pasini P, Finco B. False-positive reactions for IgA anti-phospholipid and anti-beta(2)-glycoprotein I antibodies in patients with IgA monoclonal gammopathy. Clin Chem. 1999;45:2007–10.

    PubMed  CAS  Google Scholar 

  86. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost. 1997;78:1008–14.

    PubMed  CAS  Google Scholar 

  87. Donohoe S, Mackie IJ, Isenberg D, Machin SJ. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol. 2001;113:544–9.

    Article  PubMed  CAS  Google Scholar 

  88. Palosuo T, Virtamo J, Haukka J, et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men—a nested case-control study. Thromb Haemost. 1997;78:1178–82.

    PubMed  CAS  Google Scholar 

  89. Tsutsumi A, Hayashi T, Chino Y, et al. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Mod Rheumatol. 2006;16:158–64.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  90. Binder W, Lewis S, Shums Z. Clinical significance of IgG and IgM autoantibodies that target the complex of phosphatidylserine and prothrombin. Lupus. 2010;19:C134 (abstract).

    Google Scholar 

Download references

Acknowledgments

Maria Laura Bertolaccini is funded by the Louise Gergel Fellowship. Bas de Laat is funded by a personal grant of the Netherlands Heart Foundation (NHS2006T053). Olga Amengual is funded by the Japanese Society for the Promotion of the Science (JSPS) and the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)(ID 0940106, Project number 21-40106). The work presented by Jacob H. Rand was supported by grants RO1 HL-61331 and RC1 HL101031 from the National Institutes of Health /the National Heart Lung and Blood Institute. The Hopkins Lupus Cohort is supported by a grant from NIH (AR 43727), and by Grant Number UL1 RR 025005 from the National Center for Research Resources (NCRR).

Author information

Authors and Affiliations

  1. Division of Women’s Health, Lupus Research Unit, The Rayne Institute, King’s College London, St Thomas’ Hospital, Westminster Bridge Road, 4th Floor, Lambeth Wing, London, SE1 7EH, UK

    Maria Laura Bertolaccini MD, PhD

  2. Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    Olga Amengual MD, PhD & Tatsuya Atsumi MD, PhD

  3. Department of Research and Development, INOVA Diagnostics Inc., San Diego, CA, USA

    Walter L. Binder PhD

  4. Department of Obstetrics and Gynecology, University of Tennessee Health Sciences Center, Memphis, TN, USA

    William H. Kutteh MD, PhD

  5. Department of Biochemistry, Maastricht University Medical Center, Maastricht, Limburg, The Netherlands

    Bas de Laat PhD

  6. Department of Hematology, Favaloro University, Buenos Aires, Argentina

    Ricardo Forastiero PhD

  7. Department of Internal Medicine, Chru Lille, Lille, France

    Marc Lambert MD, PhD

  8. Department of Obstetrics and Gynecology, Osaka New ART Clinic, Osaka, Osaka-fu, Japan

    Hidehiko Matsubayashi MD, PhD

  9. Department of Rheumatology, University of Texas Medical Branch, Galveston, TX, USA

    Vijaya L. Murthy MBBS

  10. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Michelle Petri MD, MPH

  11. Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA

    Jacob H. Rand MD

  12. Department of Immunology, Hôpital de la Conception, Marseille, France

    Marielle Sanmarco MD

  13. Department of Pathology, University of Utah & ARUP Laboratories, Salt Lake City, UT, USA

    Anne E. Tebo PhD

  14. Division of Rheumatology, Department of Internal Medicine, Microbiology and Pathology, University of Texas Medical Branch, Galveston, TX, USA

    Silvia S. Pierangeli PhD

Authors
  1. Maria Laura Bertolaccini MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olga Amengual MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatsuya Atsumi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter L. Binder PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William H. Kutteh MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bas de Laat PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ricardo Forastiero PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marc Lambert MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hidehiko Matsubayashi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vijaya L. Murthy MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michelle Petri MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jacob H. Rand MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Marielle Sanmarco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Anne E. Tebo PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Silvia S. Pierangeli PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Laura Bertolaccini MD, PhD .

Editor information

Editors and Affiliations

  1. The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, New York, NY, USA

    Doruk Erkan

  2. University of Texas Medical Branch, 301 University Boulevard, Galveston, 77555-0883, Texas, USA

    Silvia S. Pierangeli

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bertolaccini, M.L. et al. (2012). Task Force Report on “Non-criteria” Antiphospholipid Antibody Tests. In: Erkan, D., Pierangeli, S. (eds) Antiphospholipid Syndrome. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3194-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3194-7_8

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-3193-0

  • Online ISBN: 978-1-4614-3194-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation